Loading clinical trials...
Loading clinical trials...
Double-blind Placebo-controlled Clinical Trial of Ginger (Zingiber Officinale) in Prophylactic Migraine Treatment
The main objective of the study is to evaluate ginger efficacy as an prophylactic treatment of migraine.
Patients with the diagnosis of migraine according to the IHS criteria will receive capsules of 200 mg of ginger extract (5% active ingredient) or placebo (cellulose) to be taken three times a day for 12 weeks.
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
No
Ambulatório Bias Fortes
Belo Horizonte, Minas Gerais, Brazil
Start Date
April 1, 2015
Primary Completion Date
July 1, 2016
Completion Date
November 1, 2016
Last Updated
March 16, 2020
107
ACTUAL participants
Extract of ginger
OTHER
Cellulose
OTHER
Lead Sponsor
Federal University of Minas Gerais
NCT06641466
NCT07018713
NCT04715685
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions